Business ❯ Pharmaceutical Industry ❯ Market Competition

Drug Pricing

Novo Nordisk Eli Lilly Cost Analysis Insurance Coverage Consumer Health Weight Loss Solutions Compounded Drugs Access to Medication Novo Nordisk's Semaglutide Emerging Therapies Patent Issues Sales Performance Market Dominance Cost-Effectiveness Biosimilars Generic Medications Consumer Access Merck

Alumis TYK2 Pill Hits Phase 3 Goals in Psoriasis as Stock Jumps and $175 Million Offering Is Planned

The company moves to raise $175 million following the readout, signaling plans for an FDA filing in the second half of 2026.

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

FDA OKs RVO Use and Monthly Dosing for Regeneron’s Eylea HD

Merck’s Oral PCSK9 Pill Matches Injectables in Phase 3, Setting Up 2026 FDA Bid

FDA Approves Keytruda QLEX, a Rapid Subcutaneous Option for Most Adult Solid Tumor Uses